(2R)-1-methoxy-3-phenylpropan-2-amine hydrochloride | 64715-81-7

• 物质功能分类: 有机原料 - 氨基化合物 - 无环单胺、多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R)-1-methoxy-3-phenylpropan-2-amine hydrochloride
• 英文别名: (S)-(-)-2-amino-1-methoxy-3-phenylpropane hydrochloride；(2R)-1-methoxy-3-phenylpropan-2-amine;hydrochloride
• CAS: 64715-81-7
• 化学式: C₁₀H₁₅NO*ClH
• 分子量: 201.696
• InChiKey: FTMKEFCCBFJBJI-HNCPQSOCSA-N

物化性质

• 熔点：
  149-151 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.62
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  35.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 安全说明：
  S22,S24/25
• WGK Germany：
  3
• 海关编码：
  2922199090

反应信息

• 作为反应物：
  描述：

  (2R)-1-methoxy-3-phenylpropan-2-amine hydrochloride 在 盐酸 、 lithium aluminium tetrahydride 、 正丁基锂 、 甲酸 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  The preparation of novel chiral auxiliaries SAMIQ/RAMIQ and their application in the asymmetric Michael addition

  摘要：

  A pair of novel chiral auxiliaries SAMIQ/RAMIQ was synthesized from L- or D-phenylalanine methyl ester hydrochloride over six steps in 45.8% and 44.4% yield, respectively. The SAMIQ-/RAMIQ-hydrazone methodology was applied for the asymmetric Michael addition of ketones to alpha,beta-unsaturated carboxylic acid methyl esters, which afforded 3-substituted-5-oxo-alkanoates in moderate to good yield (65-82%) with excellent enantioselectivity (ee=95.3%similar to>99.5%). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.05.049
• 作为产物：
  描述：

  N-乙酰基-D-苯基丙氨酸甲酯 在 盐酸 、 锂硼氢 、 sodium hydride 作用下， 以 四氢呋喃 、 水 、 mineral oil 为溶剂， 反应 29.0h， 生成 (2R)-1-methoxy-3-phenylpropan-2-amine hydrochloride
  参考文献：
  名称：

  The preparation of novel chiral auxiliaries SAMIQ/RAMIQ and their application in the asymmetric Michael addition

  摘要：

  A pair of novel chiral auxiliaries SAMIQ/RAMIQ was synthesized from L- or D-phenylalanine methyl ester hydrochloride over six steps in 45.8% and 44.4% yield, respectively. The SAMIQ-/RAMIQ-hydrazone methodology was applied for the asymmetric Michael addition of ketones to alpha,beta-unsaturated carboxylic acid methyl esters, which afforded 3-substituted-5-oxo-alkanoates in moderate to good yield (65-82%) with excellent enantioselectivity (ee=95.3%similar to>99.5%). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2014.05.049

文献信息

• [EN] PHENETHYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS WITH AN N-1 BRANCHED GROUP<br/>[FR] COMPOSÉS IMIDAZO[4,5-C]QUINOLINE À SUBSTITUTION PHÉNÉTHYLE AYANT UN GROUPE RAMIFIÉ EN N-1
  申请人：3M INNOVATIVE PROPERTIES CO

  公开号：WO2020250089A1

  公开（公告）日：2020-12-17

  Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

  本文披露了具有通过支链基团连接在N-1位置的取代基的咪唑并[4,5-c]喹啉化合物，这些化合物的单对映异构体，含有这些化合物的药物组合物以及制备这些化合物的方法。还披露了这些化合物作为免疫应答调节剂的使用方法，用于诱导人类和动物中的细胞因子生物合成，并用于治疗包括传染性疾病和肿瘤性疾病在内的疾病的方法。
• Model solid-state reactions for the formation of a peripheral layer of organometallic dendrimers. Solid-state α-ferrocenylethylation of phenols
  作者：N. S. Khrushcheva、E. E. Belousova、N. M. Loim、V. I. Sokolov

  DOI：10.1007/bf02494904

  日期：2000.6

  With the aim of modifying solid dendrite structures, the solid-state reactions of (S)-(−)-(1-trimethylammonio)ethylferrocene iodide with substituted phenols were studied.

  为了改变固体枝晶结构，研究了（S）-（-）-（1-三甲基铵基）乙基二茂铁碘化物与取代酚的固相反应。
• Organic Compounds
  申请人：Ehara Takeru

  公开号：US20090192148A1

  公开（公告）日：2009-07-30

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds have the formula I′ wherein R1, R2, T, R3 and R4 areas defined in the specification.

  本发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=失调）；该类化合物用于制备治疗依赖肾素活性疾病的制剂；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的制药配方和/或包括给予3,5-取代哌啶化合物的治疗方法，以及制造3,5-取代哌啶化合物的新型中间体和部分合成步骤。该化合物的式子为I'，其中R1、R2、T、R3和R4在规范中有定义。
• 3 , 5-substitued piperidine compounds as renin inhibitors
  申请人：Novartis AG

  公开号：EP2420491A1

  公开（公告）日：2012-02-22

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3, 5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The compounds (which can also be present as salts) have the formula I' wherein R1, R2, T, R3, R4, R7 and R8 are as defined in the specification and R6 is OH.

  本发明涉及3,5-取代的哌啶化合物，这些化合物用于温血动物的诊断和治疗，特别是用于治疗依赖于肾素活性的疾病（=紊乱）；使用该类化合物制备药物制剂，用于治疗依赖于肾素活性的疾病；该类化合物在治疗依赖于肾素活性的疾病中的用途；包含 3,5-取代的哌啶化合物的药物制剂，和/或包括施用 3,5-取代的哌啶化合物的治疗方法，3,5-取代的哌啶化合物的制造方法，及其合成的新型中间体和部分步骤。 这些化合物（也可以以盐的形式存在）具有式 I' 其中 R1、R2、T、R3、R4、R7 和 R8 如说明书中所定义，R6 为 OH。
• 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS
  申请人：Novartis AG

  公开号：EP1968940A1

  公开（公告）日：2008-09-17